Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Slater

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Expert Review of Gastroenterology & Hepatology|October 22, 2024
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinomaBernardo Stefanini, Giulia F Manfredi, Antonio D'Alessio, et al.
The Lancet. Oncology|April 19, 2013
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialTom Waddell, Ian Chau, David Cunningham, et al.
Nature Communications|September 25, 2020
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancerHemant M Kocher, Bristi Basu, Fieke E M Froeling, et al.
Oncogene|November 20, 2019
BRF1 accelerates prostate tumourigenesis and perturbs immune infiltrationCarolyn J Loveridge, Sarah Slater, Kirsteen J Campbell, et al.
Oncogene|December 21, 2019
Correction: BRF1 accelerates prostate tumourigenesis and perturbs immune infiltrationCarolyn J Loveridge, Sarah Slater, Kirsteen J Campbell, et al.
British Journal of Cancer|August 4, 2020
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumoursRebecca Kristeleit, Jeffry Evans, L Rhoda Molife, et al.
The Lancet. Oncology|October 22, 2024
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysisAntonio D'Alessio, Bernardo Stefanini, Julia Blanter, et al.
Journal for Immunotherapy of Cancer|June 21, 2023
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humansVictoire Cardot-Ruffino, Naima Bollenrucher, Luisa Delius, et al.
Cancer Cell|May 8, 2026
Dendritic cell redundancy enables priming of anti-tumor CD4<sup>+</sup> T cells in pancreatic cancerCourtney T S Kureshi, Michael J Walsh, Rakeeb Kureshi, et al.
JCO Precision Oncology|September 2, 2025
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic CancerRishi Surana, Micaela Morgado, Ashwin Somasundaram, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Expert Review of Gastroenterology & Hepatology|October 22, 2024
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinomaBernardo Stefanini, Giulia F Manfredi, Antonio D'Alessio, et al.
The Lancet. Oncology|April 19, 2013
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialTom Waddell, Ian Chau, David Cunningham, et al.
Nature Communications|September 25, 2020
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancerHemant M Kocher, Bristi Basu, Fieke E M Froeling, et al.
Oncogene|November 20, 2019
BRF1 accelerates prostate tumourigenesis and perturbs immune infiltrationCarolyn J Loveridge, Sarah Slater, Kirsteen J Campbell, et al.
Oncogene|December 21, 2019
Correction: BRF1 accelerates prostate tumourigenesis and perturbs immune infiltrationCarolyn J Loveridge, Sarah Slater, Kirsteen J Campbell, et al.
British Journal of Cancer|August 4, 2020
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumoursRebecca Kristeleit, Jeffry Evans, L Rhoda Molife, et al.
The Lancet. Oncology|October 22, 2024
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysisAntonio D'Alessio, Bernardo Stefanini, Julia Blanter, et al.
Journal for Immunotherapy of Cancer|June 21, 2023
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humansVictoire Cardot-Ruffino, Naima Bollenrucher, Luisa Delius, et al.
Cancer Cell|May 8, 2026
Dendritic cell redundancy enables priming of anti-tumor CD4<sup>+</sup> T cells in pancreatic cancerCourtney T S Kureshi, Michael J Walsh, Rakeeb Kureshi, et al.
JCO Precision Oncology|September 2, 2025
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic CancerRishi Surana, Micaela Morgado, Ashwin Somasundaram, et al.
Pageof 3